Drug-Eluting Stent Approved for Diabetics
, patients receiving the Resolute stent had a lower rate of target lesion failure and target lesion revascularization than historical controls and an overall low rate of definite/probable stent thrombosis.
In two separate large randomized controlled trials, the Resolute DES matched the safety and effectiveness of Abbott's Xience V DES, which represents the market-leading platform in the U.S.
The , which enrolled nearly 2,300 patients, found the Resolute stent noninferior to Xience V, which elutes everolimus.
And a recent publication of the single-center results in the Journal of the American College of Cardiology found the Resolute and Xience stents statistically equal.
The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.
This Site and third parties who place advertisements on this Site may collect and use information about your visits to this Site and other websites in order to provide advertisements about goods and services of interest to you.
If you would like to obtain more information about these advertising practices and to make choices about online behavioral advertising, please